Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0001415889-25-015080
Filing Date
2025-06-02
Accepted
2025-06-02 09:04:08
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 6512
  Complete submission text file 0001415889-25-015080.txt   8205
Mailing Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478
Business Address 3 SUGAR CREEK CTR. BLVD. STE 525 SUGAR LAND TX 77478 (713) 489-8654
Tvardi Therapeutics, Inc. (Subject) CIK: 0001346830 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G | Act: 34 | File No.: 005-87880 | Film No.: 251013278
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address AVEO PHARMACEUTICALS, INC. 75 SIDNEY STREET CAMBRIDGE MA 02139
Business Address
DePinho Ronald A (Filed by) CIK: 0001486420 (see all company filings)

Type: SCHEDULE 13G